Business Description
BeiGene Ltd
NAICS : 325412
SIC : 2834
ISIN : KYG1146Y1017
Share Class Description:
HKSE:06160: Ordinary SharesCompare
Compare
Traded in other countries / regions
BGNE.USA06160.Hong Kong688235.China49B.GermanyB1GN34.BrazilBGNE.Mexico IPO Date
2018-08-08Description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.38 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | -1.38 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.49 | |||||
| Beneish M-Score | -1.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 85.3 | |||||
| 3-Year EBITDA Growth Rate | 18 | |||||
| 3-Year EPS without NRI Growth Rate | 24.3 | |||||
| 3-Year FCF Growth Rate | 2.4 | |||||
| 3-Year Book Growth Rate | -7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 30.54 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.69 | |||||
| 9-Day RSI | 45.37 | |||||
| 14-Day RSI | 47.17 | |||||
| 6-1 Month Momentum % | 52.74 | |||||
| 12-1 Month Momentum % | 32.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.98 | |||||
| Quick Ratio | 1.75 | |||||
| Cash Ratio | 1.34 | |||||
| Days Inventory | 305.21 | |||||
| Days Sales Outstanding | 45.53 | |||||
| Days Payable | 253.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.4 | |||||
| Shareholder Yield % | -1.23 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.98 | |||||
| Operating Margin % | -28.62 | |||||
| Net Margin % | -16.91 | |||||
| FCF Margin % | -43.8 | |||||
| ROE % | -14.69 | |||||
| ROA % | -9.21 | |||||
| ROIC % | -39.17 | |||||
| 3-Year ROIIC % | 27.56 | |||||
| ROC (Joel Greenblatt) % | -61.5 | |||||
| ROCE % | -22.02 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.03 | |||||
| PB Ratio | 6.51 | |||||
| Price-to-Tangible-Book | 6.7 | |||||
| EV-to-EBIT | -24.18 | |||||
| EV-to-Forward-EBIT | -1863.52 | |||||
| EV-to-EBITDA | -27.1 | |||||
| EV-to-Forward-EBITDA | 267.04 | |||||
| EV-to-Revenue | 6.92 | |||||
| EV-to-Forward-Revenue | 4.41 | |||||
| EV-to-FCF | -15.8 | |||||
| Price-to-Net-Current-Asset-Value | 14.87 | |||||
| Price-to-Net-Cash | 90.14 | |||||
| Earnings Yield (Greenblatt) % | -4.14 | |||||
| FCF Yield % | -5.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BeiGene Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 24,208.037 | ||
| EPS (TTM) (HK$) | -3.124 | ||
| Beta | 0.75 | ||
| Volatility % | 47.99 | ||
| 14-Day RSI | 47.17 | ||
| 14-Day ATR (HK$) | 5.86327 | ||
| 20-Day SMA (HK$) | 132.79 | ||
| 12-1 Month Momentum % | 32.48 | ||
| 52-Week Range (HK$) | 75.45 - 153 | ||
| Shares Outstanding (Mil) | 1,381.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeiGene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BeiGene Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
BeiGene Ltd Frequently Asked Questions
What is BeiGene Ltd(HKSE:06160)'s stock price today?
The current price of HKSE:06160 is HK$127.10. The 52 week high of HKSE:06160 is HK$153.00 and 52 week low is HK$75.45.
When is next earnings date of BeiGene Ltd(HKSE:06160)?
The next earnings date of BeiGene Ltd(HKSE:06160) is 2024-11-08 Est..
Does BeiGene Ltd(HKSE:06160) pay dividends? If so, how much?
BeiGene Ltd(HKSE:06160) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers